Skip to main content
Healthcare

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial

Feed excerpt — reported by STAT News

A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.